Home | Careers | Contact Us | Sitemap 
   Other Country Sites Search
Newsroom
Generic FAQs
 


Home > Newsroom  
April 2008
 
 Day : 15
Ranbaxy and AstraZeneca reach agreement in esomeprazole patent litigation
 
 
February 2008
 
 Day : 7
Ranbaxy receives tentative approval to manufacture and market Esomeprazole Magnesium dr capsules
 
 Day : 6
Ranbaxy gains approval to manufacture and market Cefuroxime axetil for oral suspension
 
 
 November 2007
 
 Day : 8
Ranbaxy and Astellas/Boehringer Ingelheim Enter Into an Agreement to Resolve Tamsulosin U.S. Patent Litigation
 
 
October 2007
 
Day : 29
Ranbaxy Receives Tentative Approval for Valsartan Tablets
 
Day : 2
Ranbaxy First to Gain Approval to Manufacture and Market Clarithromycin for Oral Suspension, USP
 
 
September 2007
 
Day : 6
Ranbaxy Gains Approval to Manufacture and Market Carvedilol Tablets in the US Market
 
 
August 2007
 
Day : 30
Ranbaxy Receives Tentative Approval to Manufacture and Market Galantamine Tablets on an Exclusive Basis
 
Day : 20
Ranbaxy Receives Approval to Manufacture and Market Hydrocodone Bitartrate and Acetaminophen Tablets USP
 
 
July 2007
 
Day : 26
Ranbaxy and GlaxoSmithKline Enter into an Agreement to Settle Valacyclovir U.S. Patent Litigation
 

Media Contacts

Chuck Caprariello
Vice President, Corporate Communications and Government Affairs
Phone: (609)720-5615
chuck.caprariello@ranbaxy.com

Edwige Buteau
Phone: (212) 994-7517
edwige.buteau@rfbinder.com

Anuj Baveja
Phone: (212) 994-7552
anuj.baveja@rfbinder.com